Analysts Expect Pfizer (PFE) to Deliver a Blowout Q3
Our preview of the upcoming week's earnings reports includes Pfizer (PFE), Square (SQ) and Moderna (MRNA).
It has been a strong earnings season so far, with about 82% of the S&P 500 companies that have reported so far exceeding analysts' earnings estimates, according to FactSet.
This week promises another jam-packed earnings calendar, with blue-chip pharmaceutical firm Pfizer (PFE, $43.55) among those releasing results.
The Dow Jones stock had a strong start to the year, rallying from its Dec. 31 close at $36.81 to its Aug. 17 record high at $50.42. Helping fuel the shares were strong sales of the company's COVID-19 vaccine – developed alongside BioNTech (BNTX). This was evidenced in PFE's second-quarter results, with vaccine revenues surging 640% year-over-year (YoY) and total revenues up 92% from the year prior. PFE shares climbed more than 3% in response.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Investors are likely hoping for another positive reaction to Pfizer's third-quarter earnings report – slated on the earnings calendar for the morning of Nov. 2 – especially considering the stock is down about 14% from that aforementioned peak.
Analysts are certainly targeting solid growth for Pfizer's September quarter. On average, they're looking for revenues of $22.8 billion and earnings per share (EPS) of $1.09 – both huge improvements over last year's $12.7 billion in sales and 72 cents per share in profits.
"Pfizer is on track to generate strong revenue and operating cash flow in 2021, with a large contribution from its COVID-19 vaccine," says Argus Research analyst David Toung, who has a Buy rating on the stock. "Since the 2Q 2021 earnings report, the company has signed additional contracts for the vaccine, which has also received Food and Drug Administration (FDA) authorization as a booster shot."
And beyond the COVID-19 vaccine, the analyst likes PFE's solid pipeline of biologics, strong research and development (R&D) capabilities, and "innovative" biopharma business, which includes "growth drivers" such as chemotherapy drug Ibrance, blood thinner Eliquis and pneumococcal conjugate vaccine Prevnar 13 among others.
However, Mizuho Securities analysts believe consensus estimates for Pfizer's third quarter are "likely too high." Specifically, they point to prescription trends from healthcare data analysis firm IQVIA and what they believe are likely lower-than-anticipated COVID-19 vaccine sales based on "orders that Pfizer has publicly announced and government websites that track actual COVID vaccine shipments."
Looking past Q3, the analysts – who have a Neutral (Hold) rating on PFE – "expect significant attention on the conference call on how management sees COVID-19 vaccine sales evolving over the next several quarters and management expectations on Pfizer's oral protease inhibitor targeting COVID-19 ahead of top-line data later this quarter."
The team will also be looking for commentary on "other mid-late stage pipeline assets, as well as Pfizer's business development priorities, as the company works to improve its 2026-2030 outlook."
Analyst: Square Q3 Will Be Soft, But Tailwinds Are Ahead
Square (SQ, $256.20), like so many other stocks, had a volatile, yet positive month of October. The shares rallied about 10% off their early month lows near $233, widening their year-to-date lead to nearly 18%.
The payments processor turned in blowout results in its second quarter – reporting triple-digit percentage growth on both the top and bottom lines from the year prior – but Jefferies analyst Trevor Williams doesn't think a repeat is in store.
"We expect fewer surprises than in the second quarter as investors brace for soft results after macro-turbulence in August, a deceleration in e-commerce and easing forex tailwinds," he writes in a note.
Longer term, though, he sees a "favorable setup" into 2022, with Square's acquisition of Australian buy-now, pay-later firm Afterpay expected to close in the first quarter and several new Cash App initiatives. He has a Buy rating on the fintech stock and says bulls "expect any near-term weakness to be short-lived."
Square will report its third-quarter earnings after the Nov. 4 close. Analysts, on average, are expecting $4.5 billion in revenues (+49.6% YoY) and earnings of 39 cents per share, a 14.7% improvement of its year-ago results.
Moderna Earnings Estimates High, But Sentiment Low
Moderna (MRNA, $342.87) is another healthcare stock that hit a record high in August but has since pulled back. The shares are down about 30% from that mid-August peak.
However, even with this pullback, Deutsche Bank analyst Emmanuel Papadakis thinks the shares are still extremely overvalued and has a Sell rating and $250 price target on the stock. As we detailed recently in our free A Step Ahead e-letter, Papadakis sees the COVID-19 vaccine maker's business as being fundamentally sound, but its valuation "looks detached from a problematic assessment of reality."
Needham analyst Joseph Stringer isn't exactly upbeat toward Moderna, either. He has a Hold rating on the shares, "based on our belief that success in COVID vaccine programs is fully reflected in the stock."
As for Moderna's Thursday morning third-quarter earnings report: the pros, on average, are looking for EPS of $9.09 compared to a per share loss of 59 cents in the year-ago period. As for revenues, they're targeting $6.2 billion – a more than 7,944% YoY improvement.
Get Kiplinger Today newsletter — free
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.
With over a decade of experience writing about the stock market, Karee Venema is the senior investing editor at Kiplinger.com. She joined the publication in April 2021 after 10 years of working as an investing writer and columnist at Schaeffer's Investment Research. In her previous role, Karee focused primarily on options trading, as well as technical, fundamental and sentiment analysis.
-
Stock Market Today: Dow Climbs 288 Points After Amazon, Intel Earnings
Post-earnings strength from Amazon and Intel helped cushion the blow of a disappointing October jobs report.
By David Dittman Published
-
Nvidia Stock Is Joining the Dow. Is It Time to Buy?
Nvidia will replace Intel in the Dow Jones Industrial Average this Friday. What does it mean for the stock?
By Dan Burrows Published
-
If You'd Put $1,000 Into Google Stock 20 Years Ago, Here's What You'd Have Today
Google parent Alphabet has been a market-beating machine for ages.
By Dan Burrows Published
-
Stock Market Today: Nasdaq Hits New High Ahead of Alphabet Earnings
The Google parent is one of several mega caps reporting earnings this week, with results due out after Tuesday's close.
By Karee Venema Published
-
Why Pfizer Stock Is Lower After a Beat-and-Raise Quarter
Pfizer stock is down Tuesday even after the drugmaker reported higher-than-expected Q3 earnings and raised its full-year outlook.
By Joey Solitro Published
-
Stock Market Today: Stocks Hit Fresh Highs on Bank Earnings, Econ News
Strong corporate profits and benign economic data once again sent equities to record levels.
By Dan Burrows Published
-
Stock Market Today: Markets Slip on Hot Inflation Print, Layoff News
Economic data continues to complicate expectations for Federal Reserve rate cuts.
By Dan Burrows Published
-
Stock Market Today: Stocks Rise in Choppy Day for Markets
Moderna was the worst S&P 500 stock today after the vaccine maker slashed its R&D budget.
By Karee Venema Published
-
Moderna Stock Plunges as Vaccine Maker Slashes R&D Budget: What to Know
Moderna stock is plunging Thursday after the COVID-19 vaccine maker announced plans to drastically cut its R&D spending to focus on new product approvals.
By Joey Solitro Published
-
Stock Market Today: Stocks Retreat Ahead of Nvidia Earnings
Markets lost ground on light volume Wednesday as traders keyed on AI bellwether Nvidia earnings after the close.
By Dan Burrows Published